External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas

BACKGROUND: The majority of women with ovarian cancer are diagnosed in late stages, and the mortality rate is high. The use of biomarkers as prognostic factors may improve the treatment and clinical outcome of these patients. We performed an external validation of the potential biomarkers CLU, ITGB3...

Descripción completa

Detalles Bibliográficos
Autores principales: Partheen, Karolina, Levan, Kristina, Österberg, Lovisa, Claesson, Ingela, Sundfeldt, Karin, Horvath, György
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754489/
https://www.ncbi.nlm.nih.gov/pubmed/19775429
http://dx.doi.org/10.1186/1471-2407-9-336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754489/
https://www.ncbi.nlm.nih.gov/pubmed/19775429
http://dx.doi.org/10.1186/1471-2407-9-336

Ejemplares similares